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Brown adipose tissue (BAT) directly regulates energy homeostasis via uncoupling of mitochondrial ATP
production and thermogenesis.Wang et al. (2014) now report that BAT controls liver lipogenesis via secretion
of the growth factor NRG4.Brown adipose tissue (BAT) is a special
type of fat that dissipates energy in
response to cold (Figure 1A), a process
also known as nonshivering thermogene-
sis (Cannon and Nedergaard, 2004;
Pfeifer and Hoffmann, 2014; Rosen and
Spiegelman, 2014). In contrast, white
adipose tissue (WAT) is the main site of
energy storage in our body. BAT-depen-
dent thermogenesis relies on the expres-
sion of uncoupling protein-1 (UCP-1),
which is only expressed in brown adipo-
cytes and uncouples mitochondrial fuel
oxidation from ATP production resulting
in heat production (Figure 1A). Although
the importance of BAT for newborns is
well-established, its role in human adults
has remained elusive until recent imaging
studies clearly revealed the presence of
metabolically active BAT in human adults
(Pfeifer and Hoffmann, 2014). The major
focus of BAT research has been on
UCP-1-mediated energy expenditure,
though BAT is also thought to regulate
whole-body metabolism through endo-
crine factors (Figure 1A) similar to WAT,
which has long been recognized as an
endocrine organ secreting adipokines
(Villarroya et al., 2013). BAT-derived auto-
crine and/or paracrine signals (Figure 1A)
include adenosine (Gnad et al., 2014)
and nitric oxide (NO) (Nisoli et al., 1998).
Moreover, BAT secretes endocrine fac-
tors, such as the thyroid hormone triiodo-
thyronine (Silva and Larsen, 1985). Wang
et al. (2014) now show that BAT controls
de novo liver lipid synthesis via Neuregulin
4 (Nrg4).
Nrg4 is member of the epidermal
growth factor (EGF) family expressed
in murine lung, heart, and adipose
tissues, with highest expression levels
in BAT. Nrg4 contains an EGF-like
domain that is released after proteolyticcleavage and acts as autocrine/paracrine
or endocrine signal. A recent study
(Rosell et al., 2014) independently identi-
fied Nrg4 to be enriched in BAT and in
inducible brown adipocytes, also known
as beige or brite cells (Pfeifer and Hoff-
mann, 2014; Rosen and Spiegelman,
2014).
To identify signaling molecules
released from BAT, Wang et al. (2014)
performed a secretome analysis across
12 mouse tissues and identified a cluster
of 26 genes enriched in BAT and induced
during brown adipocyte differentiation
including Nrg4. To determine the target
tissue of Nrg4, Wang et al. (2014) per-
formed binding assays on sections of
BAT, heart, muscle, liver, and spleen and
found that Nrg4 binding was restricted
to the liver, though the reason for this
specificity remains unclear. Heterotopic
expression and binding assays indicated
that Nrg4 may signal via ErbB3 and
ErbB4, which belong to the family of
ErbB/HER protein-tyrosine kinase recep-
tors (Figure 1B). To study Nrg4 function
in vivo, Wang et al. (2014) generated
Nrg4-deficient (Nrg4/) mice. High-fat-
fed Nrg4/ mice exhibited a significant
increase in body weight as well as an
exacerbation of insulin resistance and
fatty liver (i.e., hepatic steatosis). Nrg4/
livers showed significantly higher expres-
sion of several genes involved in de novo
lipogenesis (Figure 1B), which may
account for the predisposition of Nrg4/
mice to diet-induced hepatic steatosis. In
stark contrast, mice overexpressing Nrg4
in all adipose tissues gained significantly
less weight than controls upon high-fat
diet feeding and exhibited improved
glucose tolerance and increased insulin
sensitivity, together with significantly
reduced hepatic steatosis and hepaticCell Metabolismexpression of lipogenic genes. Analysis
of human WAT samples revealed that
NRG4 mRNA levels inversely correlated
with body fat mass and liver fat content.
Based on human and murine data, the
authors speculate that reduced Nrg4
expression may be causally linked to the
pathogenesis of nonalcoholic fatty liver
disease (NAFLD). Because of the obesity
pandemic, fatty liver also known as
NAFLD has become the most common
cause of chronic liver disease. It may be
possible that BAT counteracts NAFLD in
a 2-fold way: via secretion of Nrg4 to
inhibit hepatic de novo lipogenesis and
through the enormous capacity of acti-
vated BAT to clear nutrient lipids (Bartelt
et al., 2011) and shift lipid flux away from
the liver.
Several questions remain open re-
garding the therapeutic relevance of
the reported findings. First, it will be
important to determine whether human
adipocytes secrete Nrg4 and how this
might be regulated. Additionally, the
mechanism of Nrg4 induction in adipo-
cytes is not fully understood in mice
and will require further investigation. It
remains to be shown that Nrg4 signaling
is restricted to the liver in humans as
well. Given the wide-spread expression
of ErbB3 and ErbB4 in humans (http://
www.proteinatlas.org), Nrg4 might
target also other tissues. Rosell et al.
(2014) recently showed that condi-
tioned medium from brown adipocytes
induces neurite outgrowth in a rat
neuronal cell line expressing ErbB4.
This effect was Nrg4 dependent, sug-
gesting that adipocyte-derived Nrg4
might also be involved in the control
of the sympathetic neurons activating
brown adipocytes. Thus, Nrg4 appears
to be involved in a crosstalk between21, January 6, 2014 ª2015 Elsevier Inc. 13
Figure 1. BAT Dissipates Energy and Secretes Signaling Molecules Like Nrg4, which Regulates Liver Lipid Metabolism
(A) BAT dissipates energy in response to cold via an UCP-1-dependent mechanism (left). BAT secretes also a variety of signaling molecules (right) including
growth factors (like fibroblast growth factor 21 [FGF21]), hormones (e.g., thyroid hormone [T3]), cytokines (e.g., interleukin 6 [IL6]) and factors that act in an auto-
crine or paracrine manner like adenosine and NO. NRG4 is a member of the EGF family of extracellular ligands that is enriched in brown adipocytes.
(B) NRG4 regulates de novo lipogenesis in hepatocytes via ErbB3/4 and STAT signaling. In addition, ErbB3 and ErbB4 might induce other cellular responses like
proliferation.
Cell Metabolism
PreviewsBAT and liver as well as between brown
adipocytes and neurons. The latter might
enhance sympathetic innervation of WAT
depots during browning (Rosell et al.,
2014). Most importantly, Nrg4-depen-
dent activation of ErbB3/4 might induce
other cellular responses besides the
regulation of hepatic lipogenesis. For
instance, ErbB/HER receptors are known
to induce a variety of cellular responses,
such as mitogenesis. The ErbB3 receptor
promotes cell survival, and amplification
of this receptor has been reported for
numerous cancers. Thus, activation of
Nrg4/ErbB might have unwanted onco-
genic effects in liver and other tissues
(Figure 1B).
Overall, these novel results by Wang
et al. (2014) demonstrate the importance
of BAT for whole-body metabolism and14 Cell Metabolism 21, January 6, 2014 ª201highlight its endocrine functions. It will
be interesting to explore the therapeutic
relevance of the endocrine functions of
BAT and whether Nrg4 can be used to
treat NAFLD.REFERENCES
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